Vaxneuvance Dosage/Direction for Use

General: The vaccination schedule for VAXNEUVANCE should be based on official recommendations.
Dosage: Administer a 0.5 mL dose of VAXNEUVANCE intramuscularly.
Method of Administration: For intramuscular use only. Do not inject intravascularly.
The preferred site for injection is the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.
Pediatrics: Routine Vaccination Schedule for Infants 6 Weeks - 6 Months of Age: 4-Dose Regimen (Three-Dose Primary Series Followed by a Toddler Dose): The recommended routine infant immunization regimen consists of four doses of VAXNEUVANCE, each of 0.5 mL. The primary infant series consists of three doses, with the first dose usually given at 2 months of age and with an interval of at least 4 weeks between doses. The first dose may be given as early as six weeks of age. The fourth (booster) dose is recommended between 11 and 15 months of age and at least 2 months after the third dose.
3-Dose Regimen (Two-Dose Primary Series Followed by a Toddler Dose): Alternatively, when VAXNEUVANCE is given as part of a routine infant immunization programme, a regimen consisting of three doses, each of 0.5 mL, may be given. The first dose is usually given at 2 months of age, with a second dose 2 months later. The first dose may be given as early as six weeks of age. The third (booster) dose is recommended between 11 and 15 months of age.
Preterm Infants: Preterm infants (<37 weeks gestation at birth) should receive a 4-dose regimen (three-dose primary series followed by a toddler dose) of VAXNEUVANCE, with the first dose usually given at 2 months of age, with an interval of 4 weeks between doses in the primary series. The first dose may be given as early as six weeks of age. The fourth dose should be administered at approximately 11 through 15 months of age and at least 2 months after the third dose. [See Precautions and Individuals at Increased Risk for Pneumococcal Disease under Precautions.]
Prior Vaccination with Another Pneumococcal Conjugate Vaccine: The vaccination regimen can be completed with VAXNEUVANCE if initiated with another pneumococcal conjugate vaccine [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Catch-Up Vaccination Schedule for Children 7 Months Through 17 Years of Age: For children 7 months through 17 years of age who are pneumococcal vaccine-naïve or not fully vaccinated or completed a dosing regimen with lower-valency pneumococcal conjugate vaccines, the following catch-up schedule should be considered: Infants 7 Through 11 months of age: Three doses, with the first two doses given at least 4 weeks apart. The third dose is given after 12 months of age, separated from the second dose by at least 2 months.
Children 12 Through 23 months of age: Two doses, with an interval of 2 months between doses.
Children and adolescents 2 Through 17 years of age: One single dose.
If a previous pneumococcal conjugate vaccine was administered, at least 2 months should elapse before receiving VAXNEUVANCE.
Adults: One single dose.